Literature DB >> 24345402

Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events.

Samia Mora1, Julie E Buring, Paul M Ridker.   

Abstract

BACKGROUND: Low-density lipoprotein cholesterol (LDL-C) is the traditional measure of risk attributable to LDL. Non-high-density lipoprotein cholesterol (NHDL-C), apolipoprotein B (apoB), and LDL particle number (LDL-P) are alternative measures of LDL-related risk. However, the clinical utility of these measures may only become apparent among individuals for whom levels are inconsistent (discordant) with LDL-C. METHODS AND
RESULTS: LDL-C was measured directly, NHDL-C was calculated, apoB was measured with immunoassay, and LDL-P was measured with nuclear magnetic resonance spectroscopy among 27 533 healthy women (median follow-up 17.2 years; 1070 incident coronary events). Participants were grouped by median LDL-C (121 mg/dL) and each of NHDL-C, apoB, and LDL-P. Discordance was defined as LDL-C greater than or equal to the median and the alternative measure less than the median, or vice versa. Despite high LDL-C correlations with NHDL-C, apoB, and LDL-P (r=0.910, 0.785, and 0.692; all P<0.0001), prevalence of LDL-C discordance as defined by median cut points was 11.6%, 18.9%, and 24.3% for NHDL-C, apoB, and LDL-P, respectively. Among women with LDL-C less than the median, coronary risk was underestimated for women with discordant (greater than or equal to the median) NHDL-C (age-adjusted hazard ratio, 2.92; 95% confidence interval, 2.33-3.67), apoB (2.48, 2.01-3.07), or LDL-P (2.32, 1.88-2.85) compared with women with concordant levels. Conversely, among women with LDL-C greater than or equal to the median, risk was overestimated for women with discordant (less than the median) NHDL-C (0.40, 0.29-0.57), apoB (0.34, 0.26-0.46), or LDL-P (0.42, 0.33-0.53). After multivariable adjustment for potentially mediating factors, including HDL cholesterol and triglycerides, coronary risk remained underestimated or overestimated by ≈20% to 50% for women with discordant levels.
CONCLUSIONS: For women with discordant LDL-related measures, coronary risk may be underestimated or overestimated when LDL-C alone is used. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00000479.

Entities:  

Keywords:  lipids; lipoproteins; primary prevention

Mesh:

Substances:

Year:  2013        PMID: 24345402      PMCID: PMC4501252          DOI: 10.1161/CIRCULATIONAHA.113.005873

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  29 in total

1.  2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Philip Greenland; Joseph S Alpert; George A Beller; Emelia J Benjamin; Matthew J Budoff; Zahi A Fayad; Elyse Foster; Mark A Hlatky; John McB Hodgson; Frederick G Kushner; Michael S Lauer; Leslee J Shaw; Sidney C Smith; Allen J Taylor; William S Weintraub; Nanette K Wenger; Alice K Jacobs
Journal:  Circulation       Date:  2010-11-15       Impact factor: 29.690

Review 2.  Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy.

Authors:  Elias J Jeyarajah; William C Cromwell; James D Otvos
Journal:  Clin Lab Med       Date:  2006-12       Impact factor: 1.935

Review 3.  Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation.

Authors:  John D Brunzell; Michael Davidson; Curt D Furberg; Ronald B Goldberg; Barbara V Howard; James H Stein; Joseph L Witztum
Journal:  Diabetes Care       Date:  2008-04       Impact factor: 19.112

4.  Maternal and paternal history of myocardial infarction and risk of cardiovascular disease in men and women.

Authors:  H D Sesso; I M Lee; J M Gaziano; K M Rexrode; R J Glynn; J E Buring
Journal:  Circulation       Date:  2001-07-24       Impact factor: 29.690

5.  Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines.

Authors:  Iris Shai; Eric B Rimm; Susan E Hankinson; Gary Curhan; JoAnn E Manson; Nader Rifai; Meir J Stampfer; Jing Ma
Journal:  Circulation       Date:  2004-10-18       Impact factor: 29.690

6.  Clinical implications of discordance between low-density lipoprotein cholesterol and particle number.

Authors:  James D Otvos; Samia Mora; Irina Shalaurova; Philip Greenland; Rachel H Mackey; David C Goff
Journal:  J Clin Lipidol       Date:  2011 Mar-Apr       Impact factor: 4.766

7.  A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.

Authors:  Paul M Ridker; Nancy R Cook; I-Min Lee; David Gordon; J Michael Gaziano; Joann E Manson; Charles H Hennekens; Julie E Buring
Journal:  N Engl J Med       Date:  2005-03-07       Impact factor: 91.245

Review 8.  2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult.

Authors:  Todd J Anderson; Jean Grégoire; Robert A Hegele; Patrick Couture; G B John Mancini; Ruth McPherson; Gordon A Francis; Paul Poirier; David C Lau; Steven Grover; Jacques Genest; André C Carpentier; Robert Dufour; Milan Gupta; Richard Ward; Lawrence A Leiter; Eva Lonn; Dominic S Ng; Glen J Pearson; Gillian M Yates; James A Stone; Ehud Ur
Journal:  Can J Cardiol       Date:  2013-02       Impact factor: 5.223

9.  Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk.

Authors:  Allan D Sniderman; Annie C St-Pierre; Bernard Cantin; Gilles R Dagenais; Jean-Pierre Després; Benoît Lamarche
Journal:  Am J Cardiol       Date:  2003-05-15       Impact factor: 2.778

10.  LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study - Implications for LDL Management.

Authors:  William C Cromwell; James D Otvos; Michelle J Keyes; Michael J Pencina; Lisa Sullivan; Ramachandran S Vasan; Peter W F Wilson; Ralph B D'Agostino
Journal:  J Clin Lipidol       Date:  2007-12       Impact factor: 4.766

View more
  69 in total

1.  Differential Genetic Effects on Statin-Induced Changes Across Low-Density Lipoprotein-Related Measures.

Authors:  Audrey Y Chu; Franco Giulianini; Bryan J Barratt; Bo Ding; Fredrik Nyberg; Samia Mora; Paul M Ridker; Daniel I Chasman
Journal:  Circ Cardiovasc Genet       Date:  2015-08-13

2.  Total cholesterol/HDL-cholesterol ratio discordance with LDL-cholesterol and non-HDL-cholesterol and incidence of atherosclerotic cardiovascular disease in primary prevention: The ARIC study.

Authors:  Renato Quispe; Mohamed B Elshazly; Di Zhao; Peter P Toth; Rishi Puri; Salim S Virani; Roger S Blumenthal; Seth S Martin; Steven R Jones; Erin D Michos
Journal:  Eur J Prev Cardiol       Date:  2019-07-10       Impact factor: 7.804

3.  Safety and Efficacy of Atorvastatin in Human Immunodeficiency Virus-infected Children, Adolescents and Young Adults With Hyperlipidemia.

Authors:  Ann J Melvin; Grace Montepiedra; Lisa Aaron; William A Meyer; Hans M Spiegel; William Borkowsky; Mark J Abzug; Brookie M Best; Marilyn J Crain; Peggy R Borum; Bobbie Graham; Patricia Anthony; Katherine Shin; George K Siberry
Journal:  Pediatr Infect Dis J       Date:  2017-01       Impact factor: 2.129

4.  Association of lowering apolipoprotein B with cardiovascular outcomes across various lipid-lowering therapies: Systematic review and meta-analysis of trials.

Authors:  Safi U Khan; Muhammad U Khan; Shahul Valavoor; Muhammad Shahzeb Khan; Victor Okunrintemi; Mamas A Mamas; Thorsten M Leucker; Michael J Blaha; Erin D Michos
Journal:  Eur J Prev Cardiol       Date:  2019-09-02       Impact factor: 7.804

5.  Lipoprotein particle number and size predict vascular structure and function better than traditional lipids in adolescents and young adults.

Authors:  Elaine M Urbina; Connie E McCoy; Zhiqian Gao; Philip R Khoury; Amy S Shah; Lawrence M Dolan; Thomas R Kimball
Journal:  J Clin Lipidol       Date:  2017-06-03       Impact factor: 4.766

6.  Apolipoprotein B is associated with carotid atherosclerosis progression independent of individual cholesterol measures in a 9-year prospective study of Multi-Ethnic Study of Atherosclerosis participants.

Authors:  Brian T Steffen; Weihua Guan; Alan T Remaley; James H Stein; Mathew C Tattersall; Joel Kaufman; Michael Y Tsai
Journal:  J Clin Lipidol       Date:  2017-07-12       Impact factor: 4.766

7.  Association between discordance of LDL-C and non-HDL-C and clinical outcomes in patients with stent implantation: from the FU-Registry.

Authors:  Michiyo Shiiba; Bo Zhang; Shin-Ichiro Miura; Amane Ike; Daisuke Nose; Takashi Kuwano; Satoshi Imaizumi; Makoto Sugihara; Atushi Iwata; Hiroaki Nishikawa; Akira Kawamura; Kazuyuki Shirai; Shin'ichiro Yasunaga; Keijiro Saku
Journal:  Heart Vessels       Date:  2017-08-16       Impact factor: 2.037

Review 8.  Assessing Cardiovascular Disease Risk and Responses to Preventive Therapies in Clinical Practice.

Authors:  Kevin C Maki; Mary R Dicklin
Journal:  Curr Atheroscler Rep       Date:  2018-03-20       Impact factor: 5.113

Review 9.  Lipid Biomarkers for Risk Assessment in Acute Coronary Syndromes.

Authors:  Jeffrey W Meeusen; Leslie J Donato; Allan S Jaffe
Journal:  Curr Cardiol Rep       Date:  2017-06       Impact factor: 2.931

10.  Relation of Combined Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B With Atherosclerosis in Adults With Type 1 Diabetes Mellitus.

Authors:  Petter Bjornstad; Robert H Eckel; Laura Pyle; Marian Rewers; David M Maahs; Janet K Snell-Bergeon
Journal:  Am J Cardiol       Date:  2015-07-16       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.